Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on April 2, 2026. The filing addresses corporate governance changes regarding the Board of Directors in preparation for the 2026 Annual Meeting of Shareholders scheduled for April 6, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Nomination: The Board approved the nomination of Michael Donovan to stand for election at the 2026 Annual Meeting. Mr. Donovan is a 60-year-old Certified Public Accountant with over 36 years of experience in the life sciences industry, including a long tenure as an audit partner at Ernst & Young LLP.
- Director Retirement: John Fallon, M.D., notified the Board on April 2, 2026, that he will not seek re-election and will retire from the Board at the conclusion of the Annual Meeting. Dr. Fallon has served as a director since 2016.
Outlook, Risks, and Management Commentary
Management stated that Dr. Fallon's decision to retire is part of the Board's ongoing strategy for board refreshment and succession planning. The filing explicitly notes that the departure is not the result of any disagreement with the Company. No other risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Confirm the election results for Michael Donovan at the 2026 Annual Meeting.
- Verify the effective date of John Fallon's retirement from the Board.
- Review the updated Board composition and committee assignments following the Annual Meeting.